Research projects
Patient information
Health data
As an AI biotechnology company, Owkin’s main mission is to use AI to find the right treatment for every patient. To achieve this, Owkin conducts research projects and processes copies of a subset of patients' pseudonymized or anonymized data. This data is preselected by Owkin’s partners to align with the inclusion and exclusion criteria of our research projects.
This data includes patient health data collected by our partners (academic, public, and research institutions, or private laboratories) during patient care and clinical trials. Owkin can reuse your data for secondary research purposes if your opposition hasn’t been expressed as written consent, in compliance with applicable laws and regulations.
Owkin is aware that your health data and more generally your personal data, even if pseudonymized (the deletion of any direct identifying information), should be processed as sensible data and that you have a right to know for which research purposes your data is being processed. That is why Owkin has decided to implement more transparency on the use of your data for its research purposes in particular by creating this webpage dedicated to explaining how your personal data is used for Owkin’s research purposes as a Data Controller.
Research projects
- Assistance Publique - Hôpitaux de Paris (based in Paris- French Academic Partner)
- Hospices Civiles de Lyon (based in Lyon - French Academic Partner)
- Under Article 6 (GDPR): Legitimate interest of Owkin to to develop and improve artificial intelligence tools enabling better medical treatment (a legitimate interest assessment has been performed to assess the balance between the benefits for Owkin and risk for the patients)
- Under Article 9 (GDPR): Scientific research purposes
- Under French law: compliance with MR004
- Under Article 6 (GDPR): legitimate interest of Owkin to perform its research projects to develop, improve or validate its AI tools for better patients medical care or treatments (a LIA has been performed to assess the balance between the benefits for Owkin and risk for the patients)
- Under Article 9 (GDPR): the public interest in public health as the study will ensure high standards of quality and safety of health care and medical devices
- Under French law: compliance with MR004
- Institut Claudius Regaud (based in Toulouse - French Academic Partner)
- Gustave Roussy (based in Paris - French Academic Partner)
- Under Article 6 (GDPR): legitimate interest of Owkin to perform its research projects to develop, improve or validate its AI tools for better patients medical care or treatments (a LIA has been performed to assess the balance between the benefits for Owkin and risk for the patients)
- Under Article 9 (GDPR): the public interest in public health as the study will ensure high standards of quality and safety of health care and medical devices
- Under French law: compliance with MR004
- Unicancer (based in Paris - French Academic Partner)
- Institut Curie (based in Paris - French Academic Partner)
- Cypath-RB (based in Villeurbanne - French Non-Academic Partner)
- Under Article 6 (GDPR): legitimate interest of Owkin to perform its research projects to develop, improve or validate its AI tools for better patients medical care or treatments (a LIA has been performed to assess the balance between the benefits for Owkin and risk for the patients)
- Under Article 9 (GDPR): the public interest in public health as the study will ensure high standards of quality and safety of health care and medical devices
- Under French law: compliance with MR004